Castration Levels of Testosterone
19
1
3
10
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
11 trials with published results (58%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
15.8%
3 terminated out of 19 trials
76.9%
-9.6% vs benchmark
5%
1 trials in Phase 3/4
110%
11 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (19)
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer